Cargando…
THU092 Characterizing Immune Checkpoint Inhibitor Induced Hypophysitis In A Large Urban Health Care System
Disclosure: M. Gogerly-Moragoda: None. U. Sharif Khawaja: None. K.C. Cheesman: None. A. Leiter: None. E.J. Gallagher: Consulting Fee; Self; Novartis Pharmaceuticals, Flare Therapeutics, Seagen, SynDevRx. INTRODUCTION Over the past decade, immune checkpoint inhibitors (ICIs) have transformed cancer t...
Autores principales: | Gogerly-Moragoda, Mahalya, Khawaja, Umar Sharif, Cheesman, Khadeen C, Leiter, Amanda, Gallagher, Emily J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554541/ http://dx.doi.org/10.1210/jendso/bvad114.1172 |
Ejemplares similares
-
SUN-417 Recovery Of Central Adrenal Insufficiency In A Patient With Hypophysitis Secondary To Immune Checkpoint Inhibitors Therapy
por: Thapi, Sahityasri, et al.
Publicado: (2019) -
MON-LB077 A Large Single Institution Series of Neuroendocrine Recovery and Tumor Recurrence after Pituitary Apoplexy
por: Brown, Teresa, et al.
Publicado: (2019) -
SAT-LB49 Persistent vs Recurrent Cushing’s Disease Diagnosed Four Weeks Post-Partum
por: Nosova, Emily V, et al.
Publicado: (2020) -
Stuck at the Checkpoint: Pembrolizumab Induced Hypophysitis With ‘Normal’ Cosyntropin Response
por: Kasiri, Elnaz, et al.
Publicado: (2021) -
Characterizing Immune Checkpoint Inhibitor-Induced Hypophysitis and Obstacles in Diagnosis
por: Johnson, Jake, et al.
Publicado: (2021)